More: American Society of Clinical Oncology (ASCO) 44th Annual Meeting

ASCO 2008: Novel Approaches to Metastatic Melanoma: Understanding the Potential of Immunotherapy CME

May 30, 2008 - June 3, 2008, Chicago, Illinois

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the American Society of Clinical Oncology.

Release Date: June 30, 2008; Valid for credit through June 30, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Clinical Oncology. These materials and the related activity are not sanctioned by the American Society of Clinical Oncology or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
BMS
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss and evaluate the efficacy and safety of current monotherapy and combination therapy approaches for patients with metastatic melanoma
  2. Compare and contrast new immunomodulatory therapies in development for the treatment of patients with metastatic melanoma
  3. Describe new clinical trial data on therapies for metastatic melanoma reported at the 2008 ASCO Annual Meeting
  4. Discuss important clinical issues that influence immunotherapy and drug trial design and evaluation in patients with metastatic melanoma, including clinical endpoints, response pattern, overall response, and adverse-events profile
Authors and Disclosures

Evan M. Hersh, MD
Disclosure: Evan M. Hersh, MD, has disclosed that he has been employed by a commercial interest and owns stock, stock options, or bonds in Amplimed Corp. Dr. Hersh has also disclosed that he has received grants for clinical research from Medarex, Bristol-Myers Squibb, and Onyx/Bayer. Dr. Hersh has also disclosed that he has received grants for educational activities and served as an advisor or consultant to Abraxis Oncology.


Jeffrey S. Weber, MD, PhD
Disclosure: Jeffrey S. Weber, MD, PhD, has disclosed that he has received grants for clinical research and educational activities from Medarex and Bristol-Myers Squibb. Dr. Weber has also disclosed that he has served as an advisor or consultant to Medarex and Bristol-Myers Squibb. Dr. Weber has also disclosed that he has served as a patent holder to Medarex and Bristol-Myers Squibb.


Walter J. Urba, MD, PhD
Disclosure: Walter J. Urba, MD, PhD, has disclosed that he has served as an advisor or consultant to Medarex and Bristol-Myers Squibb.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.